- Natera reported Q3 2026 revenue of US$793.98 million and a net loss of US$59.91 million, raised full year revenue guidance above US$3b, and at the same time announced that long time executive Solomon Moshkevich would replace Steve Chapman as CEO and join the board.
- The past week also brought fresh clinical data for Signatera across multiple cancers, with studies highlighting how molecular residual disease testing may inform treatment decisions and surveillance, underscoring how Natera’s oncology franchise is shaping its operating profile even as profitability remains under pressure.
- We will now look at how Natera's investment narrative is affected by the surprise CEO handover alongside upgraded revenue guidance.
Scan how the Natera story fits into a broader oncology and diagnostics trend by comparing it with 35 healthcare AI stocks that are already on investors’ radar.
Natera Investment Narrative Recap
For Natera, the core belief is that molecular diagnostics, especially Signatera and the broader oncology and organ health portfolio, can keep driving higher test volumes and improved economics over time. Q3 2026 revenue of US$793.98 million and raised full year guidance above US$3b support that operating momentum, even though the company still reported a net loss of US$59.91 million.
In the near term, investors are likely to focus on two things. First, whether oncology growth and reimbursement trends remain strong enough to offset heavy R&D and SG&A spend and gradually shrink losses. Second, whether the abrupt CEO transition creates any disruption in execution, especially as management leans into higher volumes, expanding trials and rising operating costs.
The CEO switch to Solomon Moshkevich on November 5, 2026 is the announcement that ties most directly to the current setup. He has run major parts of Natera’s operations since 2011, including clinical diagnostics and oncology, where Signatera has become central to the business. That tenure and product familiarity may help reduce uncertainty around product priorities and commercial focus.
From a catalyst point of view, the key question is whether this leadership change sustains or improves execution on oncology test uptake, payer coverage and cost discipline while Natera is still loss making. Any stumble on trial outcomes, reimbursement decisions or spending control would feed directly into the biggest existing risks, which are ongoing net losses, high investment needs and an already full valuation on P/S metrics.
Natera's narrative projects US$4.8b revenue and US$405.4 million earnings by 2029. This implies 21.1% yearly revenue growth and an earnings improvement of about US$598 million from current earnings, which are a US$192.3 million loss.
Uncover why Natera's fair value indicates a 34% potential upside to its current price that could narrow quickly.
Exploring Other Perspectives
Some of the most pessimistic analysts worry that Natera’s heavy early detection and lab spending could struggle to earn its keep. Before this CEO switch and guidance hike, that group was modeling roughly US$4.5b revenue and US$718.9 million earnings by 2029, compared with US$4.8b and US$405.4 million in the baseline. This contrast shows how sharply opinions can diverge. Use this earnings release and leadership change as a fresh lens to compare those narratives for yourself.
Explore 4 other Natera fair value estimates, including one that suggests up to 10% downside from the current price.
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider forming your own view based on research and analysis.
- A great starting point for your Natera research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- See our latest analysis for Natera. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easier to evaluate Natera's overall financial health at a glance.
Looking For More Investment Ideas Beyond Natera?
If this Natera update has sharpened your thinking about risk, growth and valuation, use that same lens to scan a broader field of potential opportunities with the Simply Wall St Screener.
- Prefer quality at a discount and want businesses with stronger fundamentals than their price suggests, start with 39 high quality undervalued stocks to see which candidates fit that brief.
- If resilience matters most and you care about balance sheets that can absorb shocks, focus on the list of solid balance sheet and fundamentals (24 results) to narrow the field quickly.
- Looking for companies that the market has not crowded yet but still have solid underlying metrics, use the 19 high quality undiscovered gems to surface ideas that might not be on every watchlist.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com